<DOC>
	<DOCNO>NCT01987479</DOCNO>
	<brief_summary>This multi-center , open-label , single-arm , Phase IIIb study evaluate safety efficacy RoActemra/Actemra alone combination non-biologic disease modify antirheumatic drug ( DMARDs ) rheumatoid arthritis patient inadequate response non-biologic DMARDs</brief_summary>
	<brief_title>The Safety Efficacy RoActemra/Actemra Alone Combination With Non-biologic Antirheumatics Rheumatoid Arthritis Patients .</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Patients &gt; /= 18 year age . Patients diagnosis active RA accord revise ( 1987 ) ACR criterion EULAR/ACR ( 2010 ) criterion . Oral corticosteroid ( &lt; /= 10 mg/day prednisone equivalent ) , NSAIDs nonbiologic DMARDs permit stable dose regimen &gt; /= 4 week prior Baseline . Use effective contraception throughout study define protocol ; female patient childbearing potential pregnant . Presence clinically significant medical condition . History diverticulitis , diverticulosis require antibiotic treatment , chronic ulcerative low GI disease might predispose perforation . Current history recurrent bacterial , viral , fungal , mycobacterial , infection . Any infection require hospitalization treatment IV antibiotic within 4 week Screening oral antibiotic within 2 week Screening . Clinically significant finding lab test and/or hepatits B C , HIV screening . Active TB require treatment within previous 3 year . Evidence active malignant disease , malignancy diagnose within previous 10 year , breast cancer diagnose within previous 20 year . History alcohol , drug , chemical abuse within 1 year prior Screening . Neuropathies condition might interfere pain evaluation . Major surgery ( include joint surgery ) within 8 week prior Screening plan major surgery within 6 month follow Baseline . Rheumatic autoimmune disease RA , include systemic lupus erythematosis , mixed connective tissue disorder , scleroderma , polymyositis , significant systemic involvement secondary RA ( e.g. , vasculitis , pulmonary fibrosis Felty 's syndrome ) . Secondary Sj√∂gren 's syndrome RA permit . Functional Class IV define ACR Classification Functional Status inRheumatoid Arthritis ( Appendix 2 ) . Diagnosis juvenile idiopathic arthritis juvenile RA , and/or RA age 16 . Prior history current inflammatory joint disease RA . Exposure RoActemra/Actemra ( either IV SC ) time prior Baseline . Treatment investigational agent within 4 week ( five halflives investigational drug , whichever long ) Screening . Previous treatment celldepleting therapy , include investigational agent approve therapy , alkylating agent chlorambucil , total lymphoid irradiation . Treatment IV gamma globulin , plasmapheresis within 6 month Baseline . Immunization live/attenuated vaccine within 4 week prior Baseline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>